Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 3/20 | 0.36 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751749 | 0.94 | EIF4A3 (0.35) | XDHTTRLMNA | |
| SCHEMBL17130065 | 0.78 | XDH (0.57) | XDHKCNA6KCNA3KCNA4MAP2K1 | |
| SCHEMBL402033 | 0.75 | ALDH1A1 (0.50) | MAPTPKMCYP1A2LMNAL3MBTL1 | |
| SCHEMBL5889599 | 0.73 | MMP1 (0.39) | MAPTL3MBTL1 | |
| SCHEMBL3117809 | 0.71 | ALOX15 (0.46) | TTRKCNA6KCNA3KCNA4MAP2K1 | |
| SCHEMBL17999890 | 0.71 | MAP2K1 (0.41) | XDHTTRKCNA6KCNA3KCNA4 | |
| SCHEMBL29196651 | 0.70 | MAP2K1 (0.64) | XDHKCNA6KCNA3KCNA4MAP2K1 | |
| SCHEMBL30509203 | 0.69 | KDM4E (0.60) | MAPTLMNAL3MBTL1 | |
| SCHEMBL5323920 | 0.69 | KDM4E (0.60) | MAPTLMNAL3MBTL1 | |
| SCHEMBL20918990 | 0.68 | RAB9A (0.47) | TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709503-B2 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1664025-B1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| EP-1664025-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223801-A1 | Pyrrol derivatives with antibacterial activity | PEF1, PEPD, PELP1 | XDH 917/4885TTR 2630/4885KCNA6 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.